Shanghai ST-segment Elevation Myocardial Infarction Cohort

Recruiting

• Conditions: ST Elevation Myocardial Infarction

• Registration Number: NCT05450757
• Lead Sponsor: Ruijin Hospital

Brief Summary

ST-segment elevation myocardial infarction(STEMI) remains a major cause of morbidity and mortality worldwide, despite of the early reperfusion therapy, including fibrinolysis, primary percutaneous coronary intervention (PCI),and standardized medical treatment.To improve the prognosis of STEMI patients, the management in their hospitalization should be optimized, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through PCI (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as lipid-lowering therapy.

This study aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Detailed Description

This study is a prospective cohort study. It aims to standardized the management of STEMI patients and improve the prognosis of the STEMI patients.

Study Timeline

• Study Start: 2018-09-12
• Status Verified: 2022-07
• Study First Submitted: 2022-07-02
• Study First Submitted QC: 2022-07-06
• Last Update Submitted: 2022-07-06
• Study First Posted: 2022-07-11
• Last Update Posted: 2022-07-11
• Primary Completion: 2023-09-17
• Study Completion: 2024-09-17

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• ST elevation myocardial infarction
• Coronary angiography and percutaneous coronary intervention within 12 hours of symptom onset
• Capable and willing to provide informed conset and capable of completing study visits

Exclusion Criteria

• Cardiovascular shock at admission
• Severe physical disability
• Active malignant tumors
• Active autoimmune diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Coronary angiography	1 year	The pathological changes in culprit vessels in 1 year
MACE	0-1 year	Major adverse cardiovascular events(MACE) in one year follow-up
Left Ventricular Function	1 month, 6month and 1 year	Left ventricular end diastolic volume(LVEDV),Left ventricular end systolic volume(LVESE),Left ventricular ejection fraction(LVEF) changes within one year follow-up

Trial Locations

Locations (7)

Ruijin hospital, Shanghai Jiaotong University School of Medicine; 🇨🇳 Shanghai, Shanghai, China

Shanghai Fengxian District Central Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Fifth People's Hospital, Fudan University; 🇨🇳 Shanghai, Shanghai, China

Shanghai Jiading District Central Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Minhang District Central Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Putuo District Central Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Yangpu District Central Hospital; 🇨🇳 Shanghai, Shanghai, China